Eli Lil­ly, Ab­b­Vie in M&A ac­tion; Gilead’s on­col­o­gy deal spree; FDA puts its foot down on Mak­e­na; and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here.

I was some­what de­tached from the news this week to work on a re­port­ing project, so putting this week­ly to­geth­er was an es­pe­cial­ly help­ful ex­er­cise in re­view­ing what hap­pened. If it does the same for you, please do spread the word — or let us know what we can do bet­ter.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER